// App-Quantinova.ai

: Blastic Plasmacytoid Dendritic Cell Neoplasm Treated with Approved CD123-Targeted Therapy Tagraxofusp: The First European Real-World Evidence Prospective Registry of First-Line Adult Patients

Researchers

Presenter

  • Uwe Platzbecker

Principal Investigators

  • Emanuele Angelucci

  • Pau Montesinos

  • Roberto Massimo Lemoli

  • Alexandros Spyridonidis

  • Tariq I. Mughal

  • Carole Paley

  • Marcello Riggi

  • Mohamad Mohty

Medical Centers

  • Department of Hematology and Cellular Therapy, Hôpital Saint-Antoine, Sorbonne University, Paris, France

  • Medical Clinic and Policlinic of Hematology, Cell Therapy and Hemostaseology, University Hospital Leipzig, Leipzig, Germany

  • Clinic of Hematology, Department of Internal Medicine, IRCCS San Martino Hospital, University of Genoa, Genoa, Italy

  • Department of Internal Medicine, BMT Unit, University of Patras, Patras, Greece

  • Stemline Therapeutics, New York, NY

  • Hospital Universitari i Politècnic La Fe, Instituto de Investigación Sanitaria La Fe (IISLAFE), Valencia, Spain

  • UO Ematologia e Terapie cellulari, IRCCS Ospedale Policlinico San Martino, Genoa, Italy

  • Tufts University School of Medicine, Boston, MA

Locations

  • France

  • Italy

  • United States

  • Germany

  • Greece

  • Spain

  • Switzerland

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Blastic plasmacytoid dendritic cell neoplasm

Biomarkers

  • Neuropilin-1

  • Cluster of Differentiation 4

  • Cluster of Differentiation 56

  • Human albumin

  • Ribosomal Protein S6 Kinase A3

  • T-cell leukemia/lymphoma-1A

  • Triglyceride Level

Drug/Treatment

  • Tagraxofusp

Outcome

  • N/A

Study Design

  • Efficacy

  • Safety

  • Adaptive

  • Non Interventional

  • Single Arm

  • Prospective

  • Cohort

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved